Literature DB >> 8142260

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

M Gion1, M Plebani, R Mione, C Penzo, S Meo, A Burlina.   

Abstract

We carried out a comparison of three commonly used mucin markers, CA549, CA15.3 and MCA. Serum samples from 184 healthy women and 237 patients with primary breast cancer were evaluated. The markers were measured using commercially available immunometric assays. Like CA15.3 and MCA, CA549 was significantly associated with tumour size and lymph node status, being an effective indicator of tumour bulk. CA549 was significantly correlated with both CA15.3 and MCA. Positive/negative concordance rate was very good (93.7%) between CA549 and MCA. Conversely, CA15.3 was positive and CA549 negative in 20.4% of cases. Axillary status was not significantly different in the latter group of patients and in cases in which CA15.3 and CA549 showed concordant results. From the present findings we draw the following major conclusions: 1. CA549 and MCA are highly correlated and their association should not provide additional information; however, they should not be considered interchangeable since they may behave differently in individual cases. 2. CA549 and CA15.3, although well correlated, are discordant in a significant number of cases. Longitudinal studies are needed to verify the usefulness of the association between the two markers. 3. The three evaluated mucin markers are not interchangeable in individual patients; if a patient is monitored with a marker, she should be followed up with the same marker.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142260      PMCID: PMC1968804          DOI: 10.1038/bjc.1994.136

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.

Authors:  K R Bray; J E Koda; P K Gaur
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

2.  Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes.

Authors:  C Stähli; M Caravatti; M Aeschbacher; C Kocyba; B Takacs; H Carmann
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

3.  CA-15.3, TPA and MCA as markers for breast cancer.

Authors:  M Barak; M Steiner; B Finkel; J Abrahamson; S Antal; N Gruener
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

4.  Influence of early diagnosis on prognosis of recurrent breast cancer.

Authors:  M Stierer; H R Rosen
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

Review 5.  Tumor markers: value and limitations in the management of cancer patients.

Authors:  S E Bates; D L Longo
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

6.  Monoclonal antibodies against antigens on breast cancer cells.

Authors:  C Stähli; B Takacs; V Miggiano; T Staehelin; H Carmann
Journal:  Experientia       Date:  1985-11-15

7.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

Authors:  D Kufe; G Inghirami; M Abe; D Hayes; H Justi-Wheeler; J Schlom
Journal:  Hybridoma       Date:  1984

8.  A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer.

Authors:  E Bombardieri; M Gion; R Mione; R Dittadi; G Bruscagnin; G Buraggi
Journal:  Cancer       Date:  1989-02-01       Impact factor: 6.860

9.  An evaluation of routine follow-up for detection of breast cancer recurrences.

Authors:  A Zwaveling; G H Albers; W Felthuis; J Hermans
Journal:  J Surg Oncol       Date:  1987-03       Impact factor: 3.454

10.  A new approach to tumour marker assessment by perioperative determination in breast and colorectal cancer.

Authors:  M Gion; G Ruggeri; R Mione; R Marconato; C Casella; A Nosadini; E Simoncini; S Belloli; E Dal Zennaro; G Bruscagnin
Journal:  Int J Biol Markers       Date:  1993 Jan-Mar       Impact factor: 3.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.